ES2717757T3 - Compuestos - Google Patents
Compuestos Download PDFInfo
- Publication number
- ES2717757T3 ES2717757T3 ES15743645T ES15743645T ES2717757T3 ES 2717757 T3 ES2717757 T3 ES 2717757T3 ES 15743645 T ES15743645 T ES 15743645T ES 15743645 T ES15743645 T ES 15743645T ES 2717757 T3 ES2717757 T3 ES 2717757T3
- Authority
- ES
- Spain
- Prior art keywords
- pyrrolo
- ethoxy
- methanone
- amino
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O Chemical compound C[C@@](COCC1)N1C(c1cc(OC)c(*)cc1)=O 0.000 description 4
- ZGJVSCMCFKGKEW-UHFFFAOYSA-N CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(c(C(F)(F)F)c[nH]2)c2nc(Nc(ccc(C(N2CCOCC2)=O)c2)c2OC)n1 ZGJVSCMCFKGKEW-UHFFFAOYSA-N 0.000 description 1
- FJNNNKKFKHEAET-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCC(COC)CC2)=O)c2)c2OC)n1 FJNNNKKFKHEAET-UHFFFAOYSA-N 0.000 description 1
- MYLZMKPYMYDDHN-UHFFFAOYSA-N CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 Chemical compound CCOc1c(cc[nH]2)c2nc(Nc(ccc(C(N2CCN(C)CC2)=O)c2)c2F)n1 MYLZMKPYMYDDHN-UHFFFAOYSA-N 0.000 description 1
- DNLMWWLLGMTQII-UHFFFAOYSA-N CCOc1nc(Cl)nc2c1cn[nH]2 Chemical compound CCOc1nc(Cl)nc2c1cn[nH]2 DNLMWWLLGMTQII-UHFFFAOYSA-N 0.000 description 1
- KPSBLSBABRIUJP-UHFFFAOYSA-N CCOc1ncnc2c1cc[nH]2 Chemical compound CCOc1ncnc2c1cc[nH]2 KPSBLSBABRIUJP-UHFFFAOYSA-N 0.000 description 1
- IXUCYGQTKDSONM-UHFFFAOYSA-N COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O Chemical compound COC(c(cc1)cc(OC(F)F)c1[N+]([O-])=O)=O IXUCYGQTKDSONM-UHFFFAOYSA-N 0.000 description 1
- KMWMHGDGKNFOMV-UHFFFAOYSA-N [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O Chemical compound [O-][N+](c(ccc(C(O)=O)c1Cl)c1O)=O KMWMHGDGKNFOMV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014000140 | 2014-01-29 | ||
| PCT/CN2015/000054 WO2015113451A1 (en) | 2014-01-29 | 2015-01-28 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717757T3 true ES2717757T3 (es) | 2019-06-25 |
Family
ID=53756223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15743645T Active ES2717757T3 (es) | 2014-01-29 | 2015-01-28 | Compuestos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9815841B2 (OSRAM) |
| EP (1) | EP3099694B1 (OSRAM) |
| JP (1) | JP6474826B2 (OSRAM) |
| CN (1) | CN105980388B (OSRAM) |
| AU (2) | AU2015210554A1 (OSRAM) |
| CA (1) | CA2937430A1 (OSRAM) |
| ES (1) | ES2717757T3 (OSRAM) |
| RU (1) | RU2016134751A (OSRAM) |
| WO (1) | WO2015113451A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA118369C2 (uk) | 2014-01-29 | 2019-01-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки, що інгібують активність lrrk2 кінази |
| CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳－法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
| WO2017106771A1 (en) | 2015-12-16 | 2017-06-22 | Southern Research Institute | Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof |
| CA3050023A1 (en) * | 2017-01-25 | 2018-08-02 | Glaxosmithkline Intellectual Property Development Limited | Compounds |
| JP2020505397A (ja) * | 2017-01-25 | 2020-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｒｒｋ２キナーゼ活性を阻害するための化合物 |
| WO2018155916A2 (ko) * | 2017-02-22 | 2018-08-30 | 재단법인 대구경북첨단의료산업진흥재단 | 피롤로-피리미딘 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| PT3604304T (pt) * | 2017-03-23 | 2022-11-30 | Korea Res Inst Bioscience & Biotechnology | Composto derivado de pirrolo-piridina, método para a sua preparação e composição farmacêutica que o contém como substância ativa para prevenção ou tratamento de doenças relacionadas com proteína quinase |
| CN113614086A (zh) * | 2019-01-18 | 2021-11-05 | 沃若诺伊公司 | 吡咯并嘧啶衍生物以及包含其作为活性成分的用于预防或治疗蛋白激酶相关的疾病的药物组合物 |
| EP3915985A4 (en) * | 2019-01-18 | 2022-09-28 | Voronoi Co., Ltd. | PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE |
| CZ308800B6 (cs) * | 2019-02-12 | 2021-05-26 | Univerzita Palackého v Olomouci | Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci |
| WO2020232332A1 (en) | 2019-05-16 | 2020-11-19 | Dana-Farber Cancer Institute, Inc. | Pyrrolopyrimidine inhibitors of wild-type and mutant forms of lrrk2 |
| CN111205216B (zh) * | 2020-03-11 | 2022-03-29 | 连云港恒运药业有限公司 | 一种制备沙格列汀的方法 |
| JP7522315B2 (ja) * | 2020-10-29 | 2024-07-24 | 蘇州亜宝薬物研発有限公司 | 置換ジアリールアミン化合物及びその医薬組成物、製造方法と用途 |
| KR20220081631A (ko) | 2020-12-09 | 2022-06-16 | 보로노이 주식회사 | 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도 |
| WO2022155419A1 (en) * | 2021-01-15 | 2022-07-21 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as lrrk2 inhibitors |
| JP2024512024A (ja) | 2021-03-23 | 2024-03-18 | ハリア・セラピューティクス・インコーポレイテッド | Ｌｒｒｋ２キナーゼ阻害剤として有用なピリミジン誘導体 |
| TW202330549A (zh) | 2021-10-27 | 2023-08-01 | 丹麥商Ｈ 朗德貝克公司 | Lrrk2抑制劑 |
| CN115108991B (zh) * | 2022-06-30 | 2023-05-05 | 南京理工大学 | 一种硝仿基吡唑起爆药及其制备方法 |
| TW202412777A (zh) | 2022-09-15 | 2024-04-01 | 丹麥商Ｈ 朗德貝克公司 | 富白胺酸重複激酶2（lrrk2）抑制劑 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007504243A (ja) | 2003-09-03 | 2007-03-01 | ニューロジェン・コーポレーション | ５−アリール−ピラゾロ［４，３−ｄ］ピリミジン類、ピリジン類、ピラジン類及び関連化合物 |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| JP2009511528A (ja) * | 2005-10-13 | 2009-03-19 | グラクソ グループ リミテッド | Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群 |
| JP2009535393A (ja) | 2006-05-01 | 2009-10-01 | ファイザー・プロダクツ・インク | 置換２−アミノ縮合複素環式化合物 |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2009143404A1 (en) | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
| JP5752691B2 (ja) | 2009-09-29 | 2015-07-22 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 新規化合物 |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| HUE029196T2 (en) * | 2010-06-04 | 2017-02-28 | Hoffmann La Roche | Aminoprimidine derivatives as LRRK2 modulators |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| US8815882B2 (en) | 2010-11-10 | 2014-08-26 | Genentech, Inc. | Pyrazole aminopyrimidine derivatives as LRRK2 modulators |
| AU2011326427B2 (en) | 2010-11-10 | 2016-01-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| CN103492389B (zh) | 2011-04-21 | 2016-09-14 | 原真股份有限公司 | 用作激酶抑制剂的吡唑并[4,3-d]嘧啶 |
| CA2847540C (en) | 2011-09-22 | 2016-05-17 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
| JP6148248B2 (ja) | 2011-11-30 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２のポジトロン放出断層撮影（ｐｅｔ）イメージングのためのフッ素−１８及び炭素−１１標識放射性リガンド |
| GB201204985D0 (en) | 2012-03-21 | 2012-05-02 | Genentech Inc | Compounds |
| MX363118B (es) | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| BR112014027117B1 (pt) | 2012-05-03 | 2022-09-06 | Genentech, Inc | Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição |
| PE20150153A1 (es) * | 2012-06-29 | 2015-02-05 | Pfizer | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 |
| UA118369C2 (uk) | 2014-01-29 | 2019-01-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки, що інгібують активність lrrk2 кінази |
-
2015
- 2015-01-28 ES ES15743645T patent/ES2717757T3/es active Active
- 2015-01-28 AU AU2015210554A patent/AU2015210554A1/en not_active Abandoned
- 2015-01-28 US US15/114,857 patent/US9815841B2/en not_active Expired - Fee Related
- 2015-01-28 WO PCT/CN2015/000054 patent/WO2015113451A1/en not_active Ceased
- 2015-01-28 CA CA2937430A patent/CA2937430A1/en not_active Abandoned
- 2015-01-28 CN CN201580006294.1A patent/CN105980388B/zh not_active Expired - Fee Related
- 2015-01-28 JP JP2016549113A patent/JP6474826B2/ja not_active Expired - Fee Related
- 2015-01-28 EP EP15743645.2A patent/EP3099694B1/en active Active
- 2015-01-28 RU RU2016134751A patent/RU2016134751A/ru not_active Application Discontinuation
-
2018
- 2018-01-12 AU AU2018200271A patent/AU2018200271A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018200271A1 (en) | 2018-02-01 |
| RU2016134751A (ru) | 2018-03-02 |
| US20170022204A1 (en) | 2017-01-26 |
| US9815841B2 (en) | 2017-11-14 |
| CN105980388A (zh) | 2016-09-28 |
| EP3099694B1 (en) | 2019-01-16 |
| CN105980388B (zh) | 2018-01-16 |
| WO2015113451A1 (en) | 2015-08-06 |
| EP3099694A1 (en) | 2016-12-07 |
| EP3099694A4 (en) | 2017-06-14 |
| JP6474826B2 (ja) | 2019-02-27 |
| JP2017504635A (ja) | 2017-02-09 |
| CA2937430A1 (en) | 2015-08-06 |
| AU2015210554A1 (en) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2717757T3 (es) | Compuestos | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| JP6745824B2 (ja) | 複素環化合物 | |
| EP2883875B1 (en) | N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing the same as active ingredient for preventing or treating cancer | |
| JP2020526543A (ja) | ロイシンリッチリピートキナーゼ２の阻害剤 | |
| TW200835481A (en) | Imidazotriazines and imidazopyrimidines as kinase inhibitors | |
| WO2018137607A1 (en) | Compounds | |
| US11034696B2 (en) | Compounds for inhibiting LRRK2 kinase activity | |
| JP6698633B2 (ja) | 複素環化合物 | |
| BR112015017759B1 (pt) | Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos | |
| CN101679306B (zh) | 治疗神经变性疾病的杂芳基酰胺取代的嘧啶酮衍生物 | |
| BR112019015273A2 (pt) | compostos | |
| KR20160106623A (ko) | 화합물 | |
| US20140155375A1 (en) | Novel compounds | |
| CN105481862A (zh) | Flt3激酶的新型抑制剂及其用途 | |
| BR112019015278A2 (pt) | compostos | |
| US20190389850A1 (en) | Compounds | |
| HK40019825A (en) | Therapeutic compounds and compositions, and methods of use thereof |